Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting
10.1007/s44313-024-00048-0
- Author:
Raziyeh HAKAK
1
;
Behzad POOPAK
;
Ahmad MAJD
Author Information
1. Department of Cellular and Molecular Biology, Faculty of Biological Sciences, North Tehran Branch, Azad University, Tehran, Iran
- Publication Type:RESEARCH
- From:Blood Research
2024;59():42-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study aimed to determine the frequency of regulatory T cells (Tregs) (CD4 + /FOXP3 + ) and indoleamine 2,3-dioxygenase (IDO) expression in patients with acute myeloid leukemia (AML).
Methods:This cross-sectional case–control study was conducted between Jan 2022 and Dec 2023. Bone marrow samples were collected from 20 healthy individuals and 15 patients with AML. Flow cytometry, real-time polymerase chain reaction (PCR), and western blotting were used to evaluate the frequency of Treg and IDO expression levels.
Results:The Treg percentage among total lymphocytes was lower in the AML group than that in the normal group.However, Treg percentage among T-helper (Th) lymphocytes was significantly higher in the AML group than that in the normal group (p < 0.05). The mean IDO expression in the AML group was significantly higher than that in the normal group (p = 0.004). A significant relationship was observed between IDO expression and Treg percentage among Th lymphocytes in the AML group (correlation = 0.637; p = 0.003). Moreover, western blot analysis showed a significant increase in IDO protein intensity in the AML group compared with that in the control group (p < 0.001).A significant difference was observed between the IDO concentrations in the AML group and that in the control group (p < 0.001). In addition, a significant difference between TGF-β levels in the AML group and those in the control group (p < 0.01) was observed.
Conclusion:IDO inhibition using novel IDO inhibitors along with chemotherapy is a promising approach to overcome the immune escape mechanisms in patients with AML, who exhibit increased levels of IDO expression and Tregs.
